with the German firm’s Merck Serono division licensing various technologies used to engineer T-cells to target cancers, including its RheoSwitch platform for controlling gene expression and ...
Merck Serono, the biopharma division of the Merck Group, has announced a global licensing, co-development and commercialization deal with China's BeiGene Co., Ltd. This is the second collaboration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback